CSPG4/NG2 transcriptional activity as a prognostic marker of the postoperative clinical course of glioblastoma

• Main Authors: А. Ю. Цидулко, В. В. Кобозев, А. М. Волков, Д. В. Костромская, С. В. Айдагулова, Р. С. Киселев, Т. Ю. Прудникова, А. Л. Кривошапкин
• Format: Article
• Language: Russian
• Published: Meshalkin National Medical Research Center 2015-10-01
• Series: Патология кровообращения и кардиохирургия
• Subjects: Глиобластома; Ген CSPG4/NG2; Хондроитинсульфат протеогликан; Прогноз заболевания
• Online Access: http://journalmeshalkin.ru/index.php/heartjournal/article/view/250
• ISSN: 1681-3472; 2500-3119

<p><strong>Objective</strong>. Glioblastoma is a malignant brain tumor characterized by severe invasive growth and poor prognosis. The expression of different genes is changed in tumors, including gene <em>CSPG4/NG2</em>, which plays a significant role in the proliferation of glioblastoma cells and tumor neovascularization. The objective of our study was to evaluate the possibility of using the above gene as a prognostic marker for glioblastoma.<br /><strong>Methods.</strong> 8 patients with a diagnosis "glioblastoma" underwent clinical and molecular-biological examination. The tumor samples were fixed in RNA-later (LifeTechnologies, USA). <em>CSPG4/NG2</em> and CD44 expression was evaluated by real-time RT-PCR with GAPDH as a reference gene. The patients were divided into two groups according to the postoperative survival rate: Group 1 – less than 1 year, and Group 2 – over 1 year after surgery. <br /><strong>Results.</strong> Molecular biological studies showed a significant 4-fold increase of <em>CSPG4/NG2</em> expression level in tumors from group 1 as compared to that of group 2 patients. It was also found out that increased <em>CSPG4/NG2</em> expression in galloping tumors is in positive correlation with an increase in cancer stem-cell marker CD44 expression (Pearson coefficient 0.9514).<br /><strong>Conclusion.</strong> The data obtained suggest that <em>CSPG4/NG2</em> is a promising prognostic marker to determine optimal postoperative treatment of patients with glioblastoma.</p>